干扰素治疗慢性丙型肝炎诱发肾病综合征及甲亢1例报告
被引量：1
摘要
患者男，27岁，2010年8月发现丙型肝炎抗体阳性，既往于6岁时患急性甲型病毒性肝炎曾接受输血治疗，无肾病和甲状腺功能（甲功）异常病史及家族史，未曾使用免疫抑制剂及抗丙肝治疗。2011年4月丙型肝炎病毒载量（HCV—RNA）为8．3×10。IU／mL，诊断为慢性丙型病毒性肝炎（CHC）。2011年6月开始隔日1次注射重组人干扰素a-2b600万u，口服利巴韦林900mg／d，
出处
《山东医药》
CAS
2013年第46期106-107,共2页
Shandong Medical Journal
参考文献12
-
1Alves-Couto C,Costa-Faria L,Dias-Ribeiro D. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon α-2b and ribavirin treatment for hepatitis C[J].{H}Liver International,2006,(10):1294-1297.
-
2傅鹏,李保春,袁伟杰.慢性粒细胞白血病患者肌注干扰素α-2b诱发肾病综合征一例[J].中华肾脏病杂志,2002,18(6):437-437. 被引量：7
-
3胡欣,汤桂芳.干扰素治疗肝炎引起甲状腺功能异常临床分析[J].临床荟萃,2009,24(14):1270-1271. 被引量：2
-
4Fried MW,Shiffman ML,Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J].{H}New England Journal of Medicine,2002,(13):975-982.
-
5谢尧,范小玲,杨松.慢性丙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志（电子版）,2009,3(3):59-64. 被引量：67
-
6Verma DS,Spitzer G,Gutterman JU. Human leukocyte interferon preparation blocks granulopoietic differentiation[J].{H}Blood,1979,(06):1423-1427.
-
7Rotman Y,Katz L,Cohen M. Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C[J].{H}Journal of Viral Hepatitis,2009,(05):340-345.
-
8Suppiah V,Moldovan M,Ahlenstiel G. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy[J].{H}Nature genetics,2009,(10):1100-1104.
-
9McCarthy JJ,Li JH,Thompson A. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin[J].{H}GASTROENTEROLOGY,2010,(07):2307-2314.
-
10Tanaka Y,Nishida N,Sugiyama M. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C[J].{H}Nature genetics,2009,(10):1105-1109.
二级参考文献10
-
1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：735
-
2Rekha Cheruvattath,Marianne J. Rosati,Manjushree Gautam,Hugo E. Vargas,Jorge Rakela,Vijayan Balan. Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?[J] 2007,Digestive Diseases and Sciences(3):732～736
-
3Bohbot NL,Young J,Orgiazzi J,et al.Interferon-alpha-inducedhyperthyroidism:a three-stage evolution from silent thyroiditistowards Graves‘disease[].European Journal of Endocrinology.2006
-
4Masood N,Ghori R,Memon A,et al.Frequency of thyroiddisorders during interferon and ribavirin therapy in chronichepatitis C infection[].J Coll Physicians Surg Pak.2008
-
5Tomer Y,Blackard JT,Akeno N.Interferon alpha treat ment andthyroid dysfunction[].Journal of Endocrinology and Metabolism.2007
-
6Jamil KM,Leedman PJ,Kontorinis N,et al.Interferon-inducedthyroid dysfunction in chronic hepatitis C[].Journal of Gastroenterology and Hepatology.2008
-
7Obolonczyk L,Obolonczyk L,Siekierska-Hell mann M,et al.Sideeffects during interferon-alpha therapy of hepatitis C withspecial consideration of thyroid dysfunction[].Postepy HigMed Dosw.2008
-
8Flink HJ,Sprengers D,Hansen BE,van Zonneveld M,de Man RA,Schalm SW,et al.Flares in chronic hepatitis B patients induced by the host or the virus?Relation to treatment response during Peg-interferon{alpha}-2b therapy[].Gut.2005
-
9Ringold D A,Nicoloff J T,Kesler M,et al.Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study[].Thyroid.2002
-
10Kee KM,Lee CM,Wang JH,Tung HD,Changchien CS,Lu SN,Wang PW.Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis[].Journal of Gastroenterology.2006
共引文献73
-
1潘祥坡,王焕新,韩云霞.干扰素治疗乙肝致蛋白尿3例[J].齐鲁药事,2007,26(11):699-700.
-
2李秀梅,李顺天,戴晨阳,徐健,苏瑞,曹武奎,侯伟,陆伟.不同基因型慢性丙型肝炎患者的早期病毒学应答及免疫状态研究[J].中华临床感染病杂志,2013,6(3):172-174.
-
3成军.肝脏疾病新进展2009[J].中国医学前沿杂志（电子版）,2009,1(2):25-29.
-
4慢性乙型肝炎特殊患者抗病毒治疗专家共识[J].中国肝脏病杂志（电子版）,2010,2(1):44-51. 被引量：4
-
5黄乙江,黄卫华,宁军.干扰素治疗乙肝致肾病综合征一例[J].右江医学,2006,34(3):342-342. 被引量：1
-
6潘祥坡,王焕新,韩云霞.干扰素治疗乙型病毒性肝炎致蛋白尿3例[J].中国药业,2008,17(3):29-29. 被引量：1
-
7王晓,柴华旗,秦爱兰.干扰素α致肾病综合征1例报告及文献复习[J].苏州大学学报（医学版）,2009,29(2):391-392. 被引量：3
-
8慢性乙型肝炎特殊患者抗病毒治疗专家共识[J].临床肝胆病杂志,2010,26(2):131-136. 被引量：10
-
9张晓岚,安君艳.2009年消化系统疾病重要诊疗进展[J].临床荟萃,2010,25(9):737-741.
-
10丁淑芬,徐立新,姚煜.干扰素联合利巴韦林治疗慢性丙肝35例抗病毒效果及T细胞亚群变化[J].交通医学,2011,25(1):71-72. 被引量：7
同被引文献14
-
1Mc Donald SA,Hutchinson SJ,Innes HA,et al.Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C:Examining the early impact of Scotland's Hepatitis C Action Plan[J].JViral Hepat,2014,21(5):366-376.
-
2Wang Y,Zhao C,Zhang L,et al.Predictive value of interferongamma inducible protein 10 k D for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis Bpatients[J].Antiviral Res,2014,103:51-59.
-
3沈弢,龙璐,邓中平,王杰,戴立忠,陈德喜,谭德明,庄辉,鲁凤民.新型国产乙型肝炎病毒核酸定量检测试剂的质量评价[J].中华检验医学杂志,2013,36(3):280-285. 被引量：17
-
4于学英,孙胜君,荆永正.山东烟台地区丙型病毒性肝炎患者的基因分型及临床意义[J].医学检验与临床,2013(2):6-9. 被引量：3
-
5王志彬,袁旭,陈玉领,王伟.河南省濮阳市六塔村丙型病毒性肝炎疫情和危险因素调查[J].疾病监测,2013,28(7):560-563. 被引量：2
-
6张敏,韩涛,肖时湘,高英堂,朱争艳.天津市慢性丙型肝炎患者感染途径分析[J].山东医药,2013,53(31):1-3. 被引量：3
-
7常艳,郭晓磊,曾征宇,吴尚为,刘运德.丙型肝炎病毒感染者基因型的分布特征[J].中华检验医学杂志,2013,36(9):856-858. 被引量：7
-
8王玲玲,廖远泉.丙型肝炎病毒及丙型肝炎流行病学慨述[J].现代临床医学,2013,39(5):326-329. 被引量：3
-
9肖桂娥,魏绍静,张复春,陈伟烈,兰芸,饶嫚,钟剑波.广州地区丙型肝炎患者HCV基因分型研究[J].热带医学杂志,2014,14(5):589-594. 被引量：15
-
10毕蔓茹,王晓韧,王威,陈立艳,颜炳柱,杨宝山.黑龙江地区丙型病毒性肝炎病毒基因型与亚型的分布特点及临床意义[J].中国医学前沿杂志（电子版）,2014,6(9):30-32. 被引量：10
-
1刘玉,谢红.急性甲型病毒性肝炎伴血小板减少1例[J].临床军医杂志,2003,31(6):122-122. 被引量：2
-
2张穗,倪群芝,朱筱秀.T淋巴细胞亚群在急性甲型病毒性肝炎中的临床意义[J].中西医结合肝病杂志,1995,5(1):31-31. 被引量：4
-
3薄怀来,李秋梅.急性甲型病毒性肝炎早期出现意识障碍3例报告[J].工企医刊,1996,9(3):108-109.
-
4王家驹.急性甲型病毒性肝炎100例5年随访观察[J].科技通报,1989,5(4):51-52.
-
5方平,李顺炜.还原型谷胱甘肽治疗病毒性肝炎临床观察[J].安徽医药,2001,5(1):25-26. 被引量：4
-
6吕屏,姚光弼,段恕诚.急性甲型病毒性肝炎血清抑制因子的初步研究[J].上海医学,1989,12(2):75-75. 被引量：1
-
7周正荣.自拟利肝退黄汤治疗急性甲型病毒性肝炎103例疗效观察[J].现代医药卫生,2007,23(11):1693-1694.
-
8李军.意大利甲型肝炎的检出率和危险因素[J].传染病信息,1997,10(2):61-61.
-
9宁更献,陈翠英,曹来福.急性甲型病毒性肝炎合并麻疹1例[J].河北医药,2009,31(1):84-84.
-
10方平,吴同生.古拉定治疗急性甲型病毒性肝炎疗效观察[J].安徽医学,2001,22(6):68-68.
